| abstract |
The present invention relates to nicotinic acetylcholine receptor agonists of formula 1 wherein a, b, c, D and R are as defined in the specification, enantiomers, pharmaceutically acceptable salts, production methods, pharmaceutical compositions containing them and methods to use them in the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders, Alzheimer's disease, learning deficit, cognitive deficit, attention deficit, memory loss, Lewy body dementia, deficit hyperactivity disorder of attention, anxiety, schizophrenia, mania or manic depression, Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is a loss of cholinergic synapse, syndrome of changing slots; smoking suspension, nicotine addiction, pain, ulcerative colitis or irritable bowel syndrome. |